Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Leases: 2023-2024

Historic Operating Leases for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $44.4 million.

  • Iovance Biotherapeutics' Operating Leases was N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $44.4 million for FY2024, which is 33.87% down from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Operating Leases is $44.4 million, which was down 33.87% from $67.1 million recorded in FY2023.
  • Iovance Biotherapeutics' Operating Leases' 5-year high stood at $67.1 million during FY2023, with a 5-year trough of $44.4 million in FY2024.
  • In the last 2 years, Iovance Biotherapeutics' Operating Leases had a median value of $55.7 million in 2023 and averaged $55.7 million.
  • Data for Iovance Biotherapeutics' Operating Leases shows a maximum YoY slumped of 33.87% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Operating Leases (Yearly) stood at $67.1 million in 2023, then tumbled by 33.87% to $44.4 million in 2024.